Abstract Details
Activity Number:
|
128
|
Type:
|
Contributed
|
Date/Time:
|
Monday, August 4, 2014 : 8:30 AM to 10:20 AM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #311426
|
View Presentation
|
Title:
|
Single-Arm Two-Stage Phase 2 Clinical Trials with Go/No-Go/Grey-Zone Outcomes
|
Author(s):
|
Bob Zhong*+
|
Companies:
|
Johnson & Johnson
|
Keywords:
|
Phase 2 trials ;
two-stage designs ;
go/no-go/grey-zone outcomes ;
asymmetric alpha spending
|
Abstract:
|
Phase 2 clinical trials are commonly conducted as pilot studies to evaluate efficacy and safety in selected populations of patients with the disease or condition to be treated or prevented. When designing such a trial considering efficacy conclusions, people naturally think as follows: if efficacy data is very strong, a go decision should be made; if efficacy data is very weak, a no-go decision should be made; if the efficacy data is nether strong nor weak, no decision can be made (grey-zone). The designs presented in this paper match this natural thinking process with go/no-go/grey-zone outcomes. When two-stage designs are used, the stage I sample size is flexible and can cover necessary practical scenarios.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2014 program
|
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.